Group 1 - China Galaxy Asset is committed to integrating national strategic services with its core business, directing financial resources towards the pharmaceutical industry to support the "Strong Pharmaceutical Nation" mission and promote healthy development of the real economy [1] - China Galaxy Asset has implemented a market-oriented debt-to-equity swap to increase capital for Taizhou Pharmaceutical, facilitating the acceleration of high-quality industrial resource aggregation and enhancing its "R&D-incubation-industrialization" ecosystem [1] - Taizhou Pharmaceutical, a leading enterprise in Jiangsu Province, has been recognized as one of the top ten biopharmaceutical industrial parks in China, but faces pressure on its capital structure due to significant investment and long funding cycles in the construction of the pharmaceutical city [1] Group 2 - The debt-to-equity swap by China Galaxy Asset helps Taizhou Pharmaceutical reduce its asset-liability ratio and financial costs, fundamentally optimizing its capital structure and enhancing its operational capabilities and market competitiveness [2] - This initiative not only alleviates financial pressure on the enterprise but also strengthens its foundation for stable and healthy long-term development, serving as a model for local state-owned enterprises in their transformation [2] - The successful implementation of the debt-to-equity swap highlights China Galaxy Asset's role as a financial risk mitigator, social resource allocator, and service provider for the real economy, providing a reference model for financial services in the "Strong Pharmaceutical Nation" initiative [2]

Group 1: High-Quality Development Goals - Shanghai's primary goal during the "14th Five-Year Plan" is to achieve significant results in high-quality development, focusing on the real economy and effective investment in advanced manufacturing, knowledge-intensive services, and new infrastructure [2][3] - The city aims to enhance new growth drivers by accelerating the construction of a modern industrial system and promoting the transformation of traditional industries through intelligent upgrades [2][3] Group 2: Biopharmaceutical Industry - Shanghai plans to strengthen its core competitiveness in the biopharmaceutical sector by fostering collaboration between enterprises, universities, and research institutions to accelerate the industrialization of innovative drug and medical device research [7][8] - The city will support enterprises in transitioning from cost competition to quality competition through smart manufacturing and technological upgrades [7][8] Group 3: Cultural and Tourism Integration - The integration of culture, tourism, commerce, and exhibitions is seen as a key driver for enhancing consumer capacity and city image, with suggestions for optimizing the commercial value of top-tier IPs and improving both soft and hard infrastructure [5][6] - Shanghai is encouraged to support private enterprises in introducing world-class IP resources and developing a comprehensive consumer experience that includes various cultural and entertainment offerings [6] Group 4: Innovation Ecosystem - The city will continue to promote artificial intelligence innovation and deepen the "Mold Speed Space" initiative, focusing on creating a high-density ecosystem for innovation and encouraging collaboration among leading enterprises [9][10] - Investment in talent development is crucial, with proposals for establishing a research-oriented entrepreneur training mechanism to attract top talent to Shanghai [10] Group 5: Addressing Internal Competition - The issue of "involution" in competition is highlighted, with recommendations for forming cross-regional innovation alliances among leading enterprises to enhance innovation capabilities and shift from homogeneous competition to value-based competition [11][12] Group 6: Supporting Overseas Expansion - Shanghai is advised to accelerate the establishment of headquarters for overseas enterprises, leveraging its financial market and international connections to support businesses in their global expansion efforts [12][13] Group 7: Attracting International Digital Nomads - The emergence of international digital nomads presents an opportunity for Shanghai, which can leverage its advantages to create a conducive environment for remote workers [14][15] - Suggestions include establishing a one-stop service platform for international remote workers and creating a demonstration zone tailored to their needs, enhancing their experience and willingness to stay long-term [15]

此外，省政协委员、苏州市人大常委会副主任黄靖，省政协委员、苏州市政协副主席周俊，省政协 委员、苏州海关驻邮局办事处一级主办龚震等9位委员，分别围绕"抢抓机遇促进跨国公司总部经济发 展""深化制造环节与服务环节融合，推动发展服务型制造""加快推进人工智能在制造业领域创新应 用"等主题，作大会书面发言。 民营经济已在我省经济格局中占据举足轻重的地位，贡献了全省58%以上的GDP、60%以上的投资 和税收收入、80%以上的新增就业和90%以上的经营主体比重。江苏拥有入选全国民营企业500强企业 90家，其中营业收入千亿元以上企业11家，入选世界500强的3家企业均为民营企业。完善中国特色现代 企业制度，加快建设世界一流企业，是推动经济高质量发展的内在要求。省政协委员、波司登股份有限 公司董事长高晓东在大会上作题为《完善中国特色现代企业制度，加快建设更多世界一流企业》的口头 发言。他认为，当前广大民营企业在党的建设、股权优化、组织变革等方面已取得积极成效，但部分企 业在加快发展新质生产力、推进治理现代化、实现代际传承等方面仍面临挑战。为此，他提出三方面建 议：要加快推动落实民营经济促进法相关配套政策法规出台，以制度完 ...

2026年，香港资本市场正步入一轮限售股解禁高峰。 这一压力的直接来源，是2025年港股IPO市场的强势回暖——当年港股募资额跃居全球首位，大量新股在上市后6至12个月的锁定期将集中于 2026年届满，从而形成跨年度、分批次解禁的流通潮。 据证券时报记者基于Wind数据整理，截至目前，港股市场2026年全年的待解禁总市值预计高达1.72万亿港元，规模显著高于2025年全年的约6000 亿港元。市场分析人士指出，解禁在机制上并不等同于股东必然减持。那些基本面扎实、股东结构稳定、且有长期资金承接的行业龙头与绩优公 司，其股价在面对解禁压力时，通常展现出更强的抗波动韧性。 9月为承压关键时点 2025年是港股IPO市场的复苏大年，在新经济、硬科技、消费与医疗等板块带动下，港股全年募资总额突破2400亿港元，重回全球前列。大批科 技制造、生物医药、数字经济企业集中登陆主板，基石投资者、控股股东、Pre-IPO投资者构成主要限售主体。按照港交所规则，基石投资者常 规锁定期6个月，控股股东锁定期6—12个月，这意味着2025年各季度上市的新股，将在2026年对应时段形成密集解禁，呈现"上市高峰—解禁高 峰"的滞后映射关系 ...

产业是钱塘发展的硬支撑，今年钱塘全面承接全市"296X"先进制造业集群建设，聚焦"车药芯化智"重点 产业集群，力争规上工业总产值突破4200亿元，推动产业集群能级持续跃升——汽车产业整零协同再提 速，力争整车、零部件产业规模分别突破750亿、600亿元，形成上下游联动发展的良好生态；"中国医 药港"持续发力创新药研发，全力冲刺上市I类创新药2个，推动生物医药产业规模突破260亿元，筑牢生 命健康产业高地；"中国芯谷"加大高端项目招引力度，计划引入高端半导体项目16个，推动半导体产业 规模突破850亿元。 "我们将持续补链强链，完善本地集成电路生态，为AI存算提供关键支撑。"作为受邀列席的企业家代 表，浙江力积存储科技股份有限公司总经理于晓的表示，正是钱塘智造企业深耕实业、奋勇争先的生动 缩影。 商报讯(记者陈敏娜通讯员钱塘宣)春潮涌动启新程，凝心聚力谋发展。昨天，钱塘区第一届人民代表大 会第六次会议开幕。聆听今年的政府工作报告，让人深感振奋——报告回顾了2025年主要工作及"十四 五"发展成绩，并明确了"十五五"发展主要目标任务和2026年重点工作。 "十四五"期间，钱塘交出了一份亮眼答卷：地区生产总值从20 ...

Core Viewpoint - The approval of the "Biopharmaceutical Industry Chain Open Innovation Development Plan" by the State Council provides opportunities for Jiangsu Province to strengthen and expand its leading position in the biopharmaceutical industry during the 14th Five-Year Plan period [1] Group 1: Policy Recommendations - Strengthen integrated policy supply and enhance service effectiveness by implementing an "Excellence Cultivation Plan" for innovative pharmaceutical companies and optimizing clinical trial subsidy application processes [1] - Promote an "early intervention, rolling submission" approval pathway for innovative drugs and medical devices, and establish a "one product, one special class" service mechanism [1] - Establish a "white list" system for the import and export of research and development materials in biopharmaceuticals and streamline the approval process for drug marketing licenses and production licenses [1] Group 2: Innovation Ecosystem - Build a comprehensive innovation ecosystem to enhance core industry momentum by attracting national clinical medical research centers and major infrastructure projects to Jiangsu [1] - Accelerate the establishment of provincial smart pharmacy laboratories and leverage national university technology transfer centers to support the establishment of new R&D institutions [1] - Implement a green channel for the listing and coding of innovative medical devices and promote data governance across departments in healthcare [1] Group 3: Talent and Financial Support - Strengthen support for essential resources by establishing a joint recruitment and cross-training mechanism for top talents between research institutions and enterprises [1] - Include AI pharmaceutical algorithm engineers in the provincial key talent cultivation directory and develop a supporting system for high-end talent [1] - Innovate financing products to support the development of customized financial products such as intellectual property pledge loans and establish an international drug registration service center [1]

近日，太仓高新区召开2026年科技人才企业迎春座谈会，华钛瑞翔、航辰系统、小科智行、一目万相、 云幕智造、安东聚变、云耀深维、光年探索八家企业获评"科技八骏"。 同样在"心脏"部件上发力的，还有航辰系统(太仓)有限公司。其研发的"航空航天摆缸式叶片马达液压伺 服作动器"，刚荣获2025年中国航空学会科技进步奖一等奖。这项历时多年从北航实验室走出的技术， 突破了密封、结构、控制等关键难题，性能指标大幅优于国外同类产品，已广泛用于中航工业、航天科 技（000901）、航天科工、中国商飞等国家战略项目。 这八家企业，横跨航空材料、机载系统、汽车悬架、医疗影像、人形机器人、可控核聚变、金属3D打 印、航天贮箱制造八大前沿领域。它们中，有的成立仅数月，有的已实现规模化交付；有的专注"从0到 1"的原始创新，有的正加速"从1到100"的产业化跨越。 "八骏"中，有的在挑战能源的终极梦想。安东聚变(太仓)科技有限公司，国内首家Z箍缩聚变商业化公 司，在彭先觉院士领衔下，正以清晰的"三个五年"路线图，冲刺2040年商业化发电目标。有的在重塑制 造精度极限。云耀深维(江苏)科技有限公司，凭借源自德国弗劳恩霍夫激光技术研究所的核 ...

表：各省份"十五五"规划建议新兴产业与未来产业布局 （因篇幅较长，仅展示部分） "十五五"启航，新一轮产业变革的风向标已经清晰浮现。 火石创造通过梳理全国31个省（区、市）"十五五"规划建议，发现了一张密集交织、错位布局的"产业 地图"。从沿海经济大省到内陆新兴区域，一场围绕新兴产业和未来产业的战略竞合正在全面铺开。 | 120 | 地区 | 新兴产业 | 大米产业 | | --- | --- | --- | --- | | 昌 | | | | | | 广东 | 新能源、新材料、商业航天、低空经济、新能 源车船、集成电路、新型储能、医药和医疗器 | 量子科技、生物制造、氢能、核聚变能、 | | | | | 脑机接口、具身智能、第六代移动通信 | | | | 械、无人机、无人船 | | | | 江苏 | | 第三代半导体、氢能、生物制造、量子科 | | 2 | | 新一代信息技术、新能源、新材料、生物医药 、高端装备、航空航天、低空经济、大飞机 | 技、脑机接口、具身智能、深海深地、原 | | | | | 子级制造、第六代移动通信 | | | | 人工智能、集成电路、新能源、新材料、航空 | | | | 山东 ...

据北京市人社局大中专毕业生就业处副处长刘洋介绍，为打造覆盖企业成长全周期的政策支持网络，北 京市从服务拓展、经费保障、资源对接、人才支持等方面为大学生创业板赋能。截至目前，已累计支持 经费超2095万元，实现企业"上板"及服务全流程免费，降低创业企业运营成本。同时，聚焦大学生创业 企业"融资难、融资贵"痛点，北京市构建了"股权+债权+专项基金"的多元化融资体系，设立"青藤计 划"，重点支持创业项目从"0到1"突破，推动北京市产业引导基金投资13家大学生创业板企业。截至目 前，136家企业获得股权融资，其中40家企业融资超亿元。依托北京股权交易中心平台资源，为123家企 业对接投资机构127次，组织"科技四板"债权路演等活动，推动银行等金融机构为企业匹配信贷资源， 累计帮助企业解决各类融资需求超140亿元。 此外，本市还打造1100平方米北京市大学生创业板示范服务基地，作为大学生创业板企业孵化培育和对 外培训宣传的窗口，实现大学生创业板实体化、可视化运营。2021年，北京市大学生创业板孵化培育基 地启动设立，构建了涵盖北京大学创业训练营、中关村软件园等机构在内的20个孵化基地，为大学生创 业板企业提供从项目培育 ...

转自：智通财经 【谢锋大使会见美国药品研究与制造企业协会总裁兼首席执行官尤布尔】智通财经2月5日电，据"中国 驻美国大使馆"公众号消息，2026年2月3日，中国驻美国大使谢锋应约会见美国药品研究与制造企业协 会（PhRMA）总裁兼首席执行官尤布尔。双方就中美生物医药行业政策、两国医药合作等议题深入交 换了意见。 ...